New pneumonia vaccine passes first safety check in small study

NCT ID NCT06611033

Completed ⭐️ VACCINE ⭐️ Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new vaccine called V118 Formulation C in 65 healthy adults to see if it is safe and well-tolerated. Participants received either the new vaccine, an existing pneumonia vaccine (Prevnar 20), or a placebo. Researchers monitored for side effects like injection-site reactions and general symptoms. The study is complete, but results are not yet publicly available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: V118 Formulation C (pneumococcal vaccine candidate)
What this could lead to: If successful, this could lead to a new vaccine option to help prevent pneumococcal disease.
What could go wrong: This is an early Phase 1 trial with only 65 healthy adults, so it is too soon to know if the vaccine will be effective or safe for larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Research Centers of America ( Hollywood ) ( Site 0002)

Hollywood, Florida, 33024, United States
University of Texas Medical Branch ( Site 0001)

Galveston, Texas, 77555-1115, United States
Velocity Clinical Research, Hallandale Beach ( Site 0003)

Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.